首页 > 市场调查报告书 > 医疗设备

医学影像诊断核子医学

市场调查报告书

商品编码

1572534

放射性药物市场、机会、成长动力、产业趋势分析与预测，2024-2032

Radiopharmaceuticals Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月22日 | 出版商:

Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年，全球放射性药物市场价值为 67 亿美元，预计在预测期内将以 9.8% 的年复合成长率(CAGR) 成长。这一增长主要是由慢性病患病率不断上升、对先进诊断工具和治疗的需求不断增长以及诊断成像技术的不断进步所推动的。正子断层扫描 (PET) 和单光子发射电脑断层扫描 (SPECT) 等关键影像技术显着提高了诊断过程的准确性，提供了详细的功能和分子见解，补充了传统的解剖成像方法。

放射性药物能够提高诊断准确性，从而能够及早发现并更好地管理癌症、心血管疾病和神经系统疾病等慢性疾病，进一步推动了对放射性药物的需求。因此，人们越来越关注开发具有更高灵敏度和特异性的放射性示踪剂，这支持了市场的扩张。

整个放射性药物产业根据类型、放射性同位素、应用、来源、最终用途和地区进行分类。

按类型划分，市场分为治疗和诊断，到2023 年，诊断将占据市场的72.6%。成为影像技术的重要组成部分。

在放射性同位素中，Technetium-99m 因其良好的核特性以及在形成用于多种诊断应用的稳定放射性药物方面的多功能性而占有最大的市场份额。这种同位素以最小的辐射暴露提供高解析度成像的能力是其在医学成像中广泛应用的关键因素。

在应用方面，由于癌症盛行率不断上升以及对创新诊断和治疗的需求，预计癌症领域将显着增长。放射性药物越来越多地用于癌症检测和治疗，使该领域成为市场成长的关键驱动力。

市场也按来源细分，迴旋加速器发挥至关重要的作用，因为它们能够生产各种可立即使用的同位素，确保放射性药物生产的灵活性和安全性。

由于对先进诊断的需求不断增长以及放射性药物在改善患者治疗效果方面已被证实的临床有效性，北美在全球市场中处于领先地位。预计该地区在预测期内将出现强劲增长。

产业生态系统分析
产业影响力
- 成长动力
  - 慢性病盛行率增加
  - 对新型癌症疗法的投资不断增加
  - 诊断影像的进步
- 产业陷阱与挑战
  - 治疗和诊断程序的高成本
  - 严格的政府法规
成长潜力分析
报销场景
监管环境
技术景观
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

主要趋势
治疗性
诊断
- 宠物
- SPECT
- 其他诊断测试

第 6 章：市场估计与预测：按放射性同位素划分，2021 - 2032 年

主要趋势
鎝99m
镓68
洛丁一世
氟18
铜64
镭223
锆89
其他放射性同位素

第 7 章：市场估计与预测：按应用分类，2021 - 2032

主要趋势
癌症
- 乳癌
- 摄护腺癌
- 肺癌
- 其他癌症类型
神经病学
心臟病学
其他应用

第 8 章：市场估计与预测：按来源划分，2021 - 2032 年

主要趋势
迴旋加速器
核反应器

第 9 章：市场估计与预测：按最终用途，2021 - 2032 年

主要趋势
医院
诊断影像中心
研究和学术机构

第 10 章：市场估计与预测：按地区划分，2021 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 11 章：公司简介

Bayer AG
Bracco
Cardinal Health Inc.
Coqui Radiopharmaceuticals Corp
Curium Pharma
Eli Lilly and Company
General Electric Company
IRE ELiT
Iso-Tex Diagnostics, Inc
Jubilant Pharmova Limited
Lantheus
Novartis AG
SHINE Technologies, LLC
Telix Pharmaceuticals Limited

简介目录

Product Code: 10918

The Global Radiopharmaceuticals Market was valued at USD 6.7 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 9.8% over the forecast period. This growth is primarily driven by the increasing prevalence of chronic diseases, rising demand for advanced diagnostic tools and treatments, and ongoing technological advancements in diagnostic imaging. Key imaging techniques like Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) have significantly enhanced the accuracy of diagnostic processes, offering detailed functional and molecular insights that complement traditional anatomical imaging methods.

The demand for radiopharmaceuticals is further bolstered by their ability to improve diagnostic accuracy, enabling early detection and better management of chronic conditions such as cancer, cardiovascular diseases, and neurological disorders. As a result, there is a growing focus on developing radiotracers with improved sensitivity and specificity, which supports market expansion.

The overall radiopharmaceuticals industry is segregated based on Type, Radioisotope, Application, Source, End Use, and Region.

By type, the market is segmented into therapeutics and diagnostics, with diagnostics dominating the market at 72.6% in 2023. Radioisotopes such as Technetium-99m, Iodine-131, and Fluorine-18 are essential in imaging techniques like SPECT and PET, making them pivotal for diagnostic procedures across various medical fields.

Among radioisotopes, Technetium-99m holds the largest market share due to its favorable nuclear properties and versatility in forming stable radiopharmaceuticals for multiple diagnostic applications. The ability of this isotope to provide high-resolution imaging with minimal radiation exposure is a key factor contributing to its widespread use in medical imaging.

On the application front, the cancer segment is expected to see significant growth, driven by the increasing prevalence of cancer and the need for innovative diagnostics and therapies. Radiopharmaceuticals are increasingly used in cancer detection and treatment, making this segment a key driver of market growth.

The market is also segmented by source, with cyclotrons playing a crucial role due to their ability to produce various isotopes for immediate use, ensuring flexibility and safety in radiopharmaceutical production.

North America leads the global market, driven by the growing demand for advanced diagnostics and the proven clinical effectiveness of radiopharmaceuticals in improving patient outcomes. This region is expected to see robust growth during the forecast period.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of chronic conditions
  - 3.2.1.2 Rising investments for novel cancer therapies
  - 3.2.1.3 Advancements in diagnostic imaging
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of therapies and diagnostic procedures
  - 3.2.2.2 Stringent government regulations
3.3 Growth potential analysis
3.4 Reimbursement scenario
3.5 Regulatory landscape
3.6 Technological landscape
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Therapeutic
5.3 Diagnostics
- 5.3.1 PET
- 5.3.2 SPECT
- 5.3.3 Other diagnostic tests

Chapter 6 Market Estimates and Forecast, By Radioisotopes, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Technetium 99m
6.3 Gallium 68
6.4 Lodine I
6.5 Fluorine 18
6.6 Copper 64
6.7 Radium 223
6.8 Zirconium 89
6.9 Other radioisotopes

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Cancer
- 7.2.1 Breast cancer
- 7.2.2 Prostate cancer
- 7.2.3 Lung cancer
- 7.2.4 Other cancer types
7.3 Neurology
7.4 Cardiology
7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Source, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Cyclotron
8.3 Nuclear reactors

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Hospitals
9.3 Diagnostic imaging centers
9.4 Research and academic institutes

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa